Immunovant
IMVT
110 hedge funds and large institutions have $407M invested in Immunovant in 2021 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 45 increasing their positions, 31 reducing their positions, and 31 closing their positions.
538% more call options, than puts
Call options by funds: $56.4M | Put options by funds: $8.84M
45% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 31
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.93% less ownership
Funds ownership: 41.29% → 39.35% (-1.9%)
8% less funds holding
Funds holding: 120 → 110 (-10)
32% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 31
38% less capital invested
Capital invested by funds: $653M → $407M (-$246M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$39.8M |
| 2 |
AGM
Alpine Global Management
New York
|
+$12.6M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$12.5M |
| 4 |
Morgan Stanley
New York
|
+$11M |
| 5 |
State Street
Boston,
Massachusetts
|
+$10.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
-$102M |
| 2 |
Goldman Sachs
New York
|
-$11.7M |
| 3 |
BlackRock
New York
|
-$8.13M |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$8.06M |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$7.49M |
IMVT Hedge Fund Activity: Q2 2021 in Review
110 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Immunovant (IMVT) for Q2 2021, worth a combined $407M — down 38% from $653M a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of IMVT and 21 opened new positions — a net loss of 10 holders — while 31 trimmed existing stakes and 45 added.
The largest buyer was Woodline Partners, adding an estimated $39.8M. The largest seller was RTW Investments, exiting entirely with an estimated $102M sold.
- 110 institutional investors held Immunovant (IMVT) as of Q2 2021, down from 120 in Q1 2021.
- Funds reported $407M of Immunovant stock for Q2 2021, down 38% quarter-over-quarter.
- 21 funds opened new Immunovant positions in Q2 2021 and 31 closed out, a net change of -10 holders.
- The largest Immunovant buyer in Q2 2021 was Woodline Partners, an estimated $39.8M added.
- The largest Immunovant seller in Q2 2021 was RTW Investments, an estimated $102M sold.
Based on aggregated 13F filings for Q2 2021.